FDA Rapid Response Surveys Need Prior Consultation With Sponsors – GSK
Executive Summary
FDA should consult companies prior to launching a rapid response survey concerning their products, GlaxoSmithKline said in comments to the agency
You may also be interested in...
FDA Risk Management Tool: Physician Rapid Response Surveys
Physician rapid response surveys of physicians will help FDA make risk management decisions
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials